Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Oncocyte Corp (OCX)

Oncocyte Corp (OCX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,869
  • Shares Outstanding, K 16,835
  • Annual Sales, $ 1,500 K
  • Annual Income, $ -27,780 K
  • EBIT $ -44 M
  • EBITDA $ -42 M
  • 60-Month Beta 0.93
  • Price/Sales 24.75
  • Price/Cash Flow N/A
  • Price/Book 3.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.98 +10.61%
on 12/05/24
2.80 -21.79%
on 11/21/24
-0.56 (-20.36%)
since 11/20/24
3-Month
1.98 +10.61%
on 12/05/24
3.30 -33.64%
on 09/23/24
-1.15 (-34.43%)
since 09/20/24
52-Week
1.98 +10.61%
on 12/05/24
3.82 -42.67%
on 01/03/24
-0.62 (-22.06%)
since 12/20/23

Most Recent Stories

More News
Insider Purchase: Chief Financial Officer of $OCX (OCX) Buys 20,000 Shares

Andrea S. James, the Chief Financial Officer of $OCX ($OCX), bought 20,000 shares of the company on 12-05-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This...

OCX : 2.19 (-0.90%)
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

OCX : 2.19 (-0.90%)
Oncocyte Corp. Announces Positive Data for DetermaCNI™ Assay in Diagnosing Central Nervous System Tumors

Oncocyte Corp. reports positive findings for DetermaCNI™, a liquid biopsy assay for diagnosing central nervous system tumors.Quiver AI SummaryOncocyte Corp. has announced the publication of positive...

OCX : 2.19 (-0.90%)
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

OCX : 2.19 (-0.90%)
Oncocyte Publishes Pioneering Study Highlighting VitaGraft’s Role in Early Diagnosis of Transplant Rejection

Oncocyte's study shows its VitaGraft™ assay significantly reduces diagnosis time for kidney transplant rejection in high-risk patients.Quiver AI SummaryOncocyte Corp. has announced favorable results...

OCX : 2.19 (-0.90%)
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms 

OCX : 2.19 (-0.90%)
OncoCyte: Q3 Earnings Snapshot

OncoCyte: Q3 Earnings Snapshot

OCX : 2.19 (-0.90%)
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

OCX : 2.19 (-0.90%)
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

OCX : 2.19 (-0.90%)
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

OCX : 2.19 (-0.90%)

Business Summary

OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.

See More

Key Turning Points

3rd Resistance Point 2.38
2nd Resistance Point 2.32
1st Resistance Point 2.26
Last Price 2.19
1st Support Level 2.14
2nd Support Level 2.08
3rd Support Level 2.02

See More

52-Week High 3.82
Fibonacci 61.8% 3.12
Fibonacci 50% 2.90
Fibonacci 38.2% 2.68
Last Price 2.19
52-Week Low 1.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar